These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

237 related items for PubMed ID: 62010

  • 1. Alternative pathway of complement: demonstration and characterization of initiating factor and its properdin-independent function.
    Schreiber RD, Götze O, Müller-Eberhard HJ.
    J Exp Med; 1976 Oct 01; 144(4):1062-75. PubMed ID: 62010
    [Abstract] [Full Text] [Related]

  • 2. Alternative pathway of complement: recruitment of precursor properdin by the labile C3/C5 convertase and the potentiation of the pathway.
    Medicus RG, Götze O, Müller-Eberhard HJ.
    J Exp Med; 1976 Oct 01; 144(4):1076-93. PubMed ID: 978134
    [Abstract] [Full Text] [Related]

  • 3. A molecular concept of the properdin pathway.
    Medicus RG, Schreiber RD, Götze O, Müller-Eberhard HJ.
    Proc Natl Acad Sci U S A; 1976 Feb 01; 73(2):612-6. PubMed ID: 54923
    [Abstract] [Full Text] [Related]

  • 4. Properdin- and nephritic factor-dependent C3 convertases: requirement of native C3 for enzyme formation and the function of bound C3b as properdin receptor.
    Schreiber RD, Medicus RG, Gïtze O, Müller-Eberhard HJ.
    J Exp Med; 1975 Sep 01; 142(3):760-72. PubMed ID: 1165475
    [Abstract] [Full Text] [Related]

  • 5. C3b inactivator in the rheumatic diseases. Measurement by radial immunodiffusion and by inhibition of formation of properdin pathway C3 convertase.
    Whaley K, Schur PH, Ruddy S.
    J Clin Invest; 1976 Jun 01; 57(6):1554-63. PubMed ID: 819459
    [Abstract] [Full Text] [Related]

  • 6. Properdin: binding to C3b and stabilization of the C3b-dependent C3 convertase.
    Fearon DT, Austen KF.
    J Exp Med; 1975 Oct 01; 142(4):856-63. PubMed ID: 1185108
    [Abstract] [Full Text] [Related]

  • 7. Activation of the alternative complement pathway with rabbit erythrocytes by circumvention of the regulatory action of endogenous control proteins.
    Fearon DT, Austen KF.
    J Exp Med; 1977 Jul 01; 146(1):22-33. PubMed ID: 559720
    [Abstract] [Full Text] [Related]

  • 8. Properdin: initiation of alternative complement pathway.
    Fearon DT, Austen KF.
    Proc Natl Acad Sci U S A; 1975 Aug 01; 72(8):3220-4. PubMed ID: 1059108
    [Abstract] [Full Text] [Related]

  • 9. Novel Assays to Distinguish Between Properdin-Dependent and Properdin-Independent C3 Nephritic Factors Provide Insight Into Properdin-Inhibiting Therapy.
    Michels MAHM, van de Kar NCAJ, van den Bos RM, van der Velden TJAM, van Kraaij SAW, Sarlea SA, Gracchi V, Oosterveld MJS, Volokhina EB, van den Heuvel LPWJ.
    Front Immunol; 2019 Aug 01; 10():1350. PubMed ID: 31263464
    [Abstract] [Full Text] [Related]

  • 10. Nephritic factor: its structure and function and its relationship to initiating factor of the alternative pathway.
    Schreiber RD, Götze O, Müller-Eberhard HJ.
    Scand J Immunol; 1976 Aug 01; 5(6-7):705-13. PubMed ID: 62386
    [Abstract] [Full Text] [Related]

  • 11. Isolation and characterization of Guinea pig properidin.
    Nicholson A, Austen KF.
    J Immunol; 1977 Jan 01; 118(1):103-8. PubMed ID: 830742
    [Abstract] [Full Text] [Related]

  • 12. Control of the amplification convertase of complement by the plasma protein beta1H.
    Weiler JM, Daha MR, Austen KF, Fearon DT.
    Proc Natl Acad Sci U S A; 1976 Sep 01; 73(9):3268-72. PubMed ID: 1067618
    [Abstract] [Full Text] [Related]

  • 13. The utilization of properdin in the alternate pathway of complement activation: isolation of properdin convertase.
    Stitzel AE, Spitzer RE.
    J Immunol; 1974 Jan 01; 112(1):56-62. PubMed ID: 4130153
    [No Abstract] [Full Text] [Related]

  • 14. Association of activated properdin with complexes of properdin with C3.
    Whiteman LY, Purkall DB, Ruddy S.
    J Immunol; 1991 Aug 15; 147(4):1344-51. PubMed ID: 1869827
    [Abstract] [Full Text] [Related]

  • 15. Activation of the alternative complement pathway due to resistance of zymosan-bound amplification convertase to endogenous regulatory mechanisms.
    Fearon DT, Austen KF.
    Proc Natl Acad Sci U S A; 1977 Apr 15; 74(4):1683-7. PubMed ID: 266208
    [Abstract] [Full Text] [Related]

  • 16. Hypocomplementemia of membranoproliferative nephritis. Dependence of the nephritic factor reaction on properdin factor B.
    Ruley EJ, Forristal J, Davis NC, Andres C, West CD.
    J Clin Invest; 1973 Apr 15; 52(4):896-904. PubMed ID: 4693654
    [Abstract] [Full Text] [Related]

  • 17. Reversible activation of proactivator (factor B) of the alternative pathway without cleavage of the molecule.
    Day NK, Schreiber RD, Götze O, Müller-Eberhard HJ.
    Scand J Immunol; 1976 Apr 15; 5(6-7):715-20. PubMed ID: 981969
    [Abstract] [Full Text] [Related]

  • 18. The alternative pathway of complement activation.
    Götze O, Müller-Eberhard HJ.
    Adv Immunol; 1976 Apr 15; 24():1-35. PubMed ID: 798473
    [No Abstract] [Full Text] [Related]

  • 19. Interaction of zymosan and of activated properdin with factor D-depleted guinea pig serum: implications for the mechanism of initial C3 cleavage via the alternative complement pathway.
    Brade V, Bentley C, Bitter-Suermann D, Hadding U.
    Z Immunitatsforsch Immunobiol; 1977 Feb 15; 152(5):402-14. PubMed ID: 556571
    [Abstract] [Full Text] [Related]

  • 20. Cleavage of the third complement component (C3) and generation of the spasmogenic peptide, C3a, in human serum via the properdin pathway: demonstration of inhibitory as well as enhancing effects of epsilon-amino-caproic acid.
    Vogt W, Schmidt G, Lynen R, Dieminger L.
    J Immunol; 1975 Feb 15; 114(2 Pt 1):671-7. PubMed ID: 804510
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.